Tricyclic Antidepressants May Increase the Incidence of Non-Hodgkin Lymphoma(7/2/2008) Researchers from Denmark reported that patients who are long-term takers of tricyclic antidepressant medications have a 53% increased incidence of non-Hodgkin lymphoma (NHL). These data were also published in the July issue of Epidemiology.
Increasing Body Mass Associated with Increasing Cancer Incidence and Mortality(11/19/2007) Researchers affiliated with the UK Million Women Study have reported that increasing body mass index (BMI) is associated with an increased risk of 10 specific types of cancer out of 17 evaluated. The details of this study appeared in an early on-line publication on November 6, 2007 in the British Medical Journal.
Occupational Solvents May Increase Risk of Lymphoma(10/5/2006) Researchers from Italy have reported that occupational exposure to solvents such as benzene, xylene, and toluene may increase the risk of developing non-Hodgkin’s lymphoma (NHL) and Hodgkin’s lymphoma (HL).
Fruits and Vegetables May Drastically Decrease Risk of Non-Hodgkin’s Lymphoma(6/27/2006) Researchers from Italy have reported that a high intake of fruits and vegetables may significantly decrease the risk of developing non-Hodgkin’s lymphoma (NHL). The details of this study appeared in the June 1, 2006, issue of the International Journal of Cancer .
Statins May Decrease Risk of Lymphoma(6/16/2006) Researchers from the Czech Republic, France, Germany, Ireland, Italy, and Spain have reported that individuals who regularly use statins may have a decreased risk of developing lymphoma. The details of this study appeared in the May 2006 issue of Cancer Epidemiology Biomarkers and Prevention.
Zevalin® Confirmed Effective for Patients with Follicular Lymphoma Who Have Failed an Autologous Transplant(9/5/2008) Researchers from France have reported that five of eight patients with follicular lymphoma who had failed an autologous stem cell transplant achieved a complete remission with standard doses of Zevalin® (Yttrium-90 ((90)Y) ibritumomab tiuxetan). The details of this study appeared in an early online publication in Leukemia-Lymphoma of July 15, 2008.
Rituxan® Maintenance in Follicular Lymphoma Deemed Cost-effective(8/27/2008) Researchers from the University of Kentucky have reported that the administration of Rituxan® (rituximab) maintenance to patients with follicular lymphoma in second remission is cost-effective. The details of this study appeared in the June 2008 issue of Clinical Lymphoma Myeloma.
BiovaxID® Improves Disease-free Survival in Non-Hodgkin’s Lymphoma(7/28/2008) Researchers from the National Cancer Institute and Accentia BioPharmaceuticals have reported that the personalized investigative vaccine BiovaxID® (personalized anti-idiotype vaccine) significantly improves cancer-free survival among patients with follicular non-Hodgkin’s lymphoma (NHL). These results were released in a press release by Accentia BioPharmaceuticals.
Maintenance Rituxan® Is Safe for Follicular Lymphoma(7/8/2008) Researchers affiliated with the International IIIb MAXIMA trial have reported that continued treatment for up to two years with Rituxan® (rituximab) is a safe therapeutic approach for the treatment of follicular lymphoma. These results were recently presented at the 2008 annual meeting of the American Society of Clinical Oncology in Chicago June 2-May 30.
Second Tumors Common in Patients with Gastric MALT Lymphoma(7/2/2008) Researchers from Germany have reported that patients with gastric mucosal associated tissue (MALT) lymphoma have high incidence of second tumors. The results of this 10-year study were reported at the 2008 meeting of the American Society of Clinical Oncology in Chicago May 30-June 2.
Zevalin® Effective for Treatment of Cutaneous B-Cell Lymphoma(8/27/2008) Researchers from Germany have reported that Zevalin® (Yttrium-90 [(90)Y] ibritumomab tiuxetan) is effective therapy for patients with primary cutaneous B-cell lymphoma (PCBCL). The details of this study appeared in an early online publication in Leukemia-Lymphoma on July 25, 2008.
Patients with Lymphoma and CLL Are at Increased Risk of Lung Cancer(6/20/2008) Researchers from Wayne State University have reported that patients with Hodgkins lymphoma (HL), non-Hodgkins lymphoma (NHL), and chronic lymphocytic leukemia (CLL) have a 30-300% increased risk of developing lung cancer compared with controls without these diseases. The details of this study were reported at the 2008 meeting of the American Society of Clinical Oncology in Chicago, May 30-June 2.
Results of Treating NHL Patients over the Age of 80 Reported at ASCO(6/12/2008) Two studies presented at the 2008 meeting of the American Society of Clinical Oncology in Chicago, May 30-June 2, suggest that aggressive therapy can be administered successfully to patients with non-Hodgkin’s lymphoma (NHL) who are 80 years of age or older.
Smoking and Heavy Alcohol Consumption Reduce Survival in Non-Hodgkin’s Lymphoma(5/28/2008) Researchers from Italy have reported that patients diagnosed with non-Hodgkin’s lymphoma (NHL) who smoke tobacco products and/or drink large quantities of alcohol have a reduced chance of survival. These results were recently published in the April 1, 3008 issue of the International Journal of Cancer.
Statins May Reduce Effectiveness of Rituxan® in Non-Hodgkin’s Lymphoma(4/3/2008) Researchers from Poland have reported that statins may reduce the effectiveness of Rituxan® (rituximab) in treatment of non-Hodgkin’s lymphoma (NHL). The details of this study were published online in PLoS Med (the Public Library of Science journal) on March 25, 2008.
Patients with Lymphoma and CLL Are at Increased Risk of Lung Cancer(6/20/2008) Researchers from Wayne State University have reported that patients with Hodgkins lymphoma (HL), non-Hodgkins lymphoma (NHL), and chronic lymphocytic leukemia (CLL) have a 30-300% increased risk of developing lung cancer compared with controls without these diseases. The details of this study were reported at the 2008 meeting of the American Society of Clinical Oncology in Chicago, May 30-June 2.
Results of Treating NHL Patients over the Age of 80 Reported at ASCO(6/12/2008) Two studies presented at the 2008 meeting of the American Society of Clinical Oncology in Chicago, May 30-June 2, suggest that aggressive therapy can be administered successfully to patients with non-Hodgkin’s lymphoma (NHL) who are 80 years of age or older.
Smoking and Heavy Alcohol Consumption Reduce Survival in Non-Hodgkin’s Lymphoma(5/28/2008) Researchers from Italy have reported that patients diagnosed with non-Hodgkin’s lymphoma (NHL) who smoke tobacco products and/or drink large quantities of alcohol have a reduced chance of survival. These results were recently published in the April 1, 3008 issue of the International Journal of Cancer.
Statins May Reduce Effectiveness of Rituxan® in Non-Hodgkin’s Lymphoma(4/3/2008) Researchers from Poland have reported that statins may reduce the effectiveness of Rituxan® (rituximab) in treatment of non-Hodgkin’s lymphoma (NHL). The details of this study were published online in PLoS Med (the Public Library of Science journal) on March 25, 2008.
High-dose Methotrexate Provides Long-term Results in Central Nervous System Lymphoma(2/19/2008) Researchers affiliated with the NABITT trial have reported that high-dose methotrexate can provide long-term responses among patients with primary central nervous system lymphoma (PCNSL). These results were published in the January 2008 issue of Neurology.
Second Autologous Stem Cell Transplants Feasible After Relapse of Lymphoma(9/4/2008) Researchers affiliated with the Center for International Blood and Marrow Transplant Research have reported that approximately one-third of patients who receive a second autologous stem cell transplant are alive and disease-free at five years. The details of this study appeared in the August 2008 issue of Biology of Blood and Marrow Transplantation.
Zevalin® Effective for Treatment of Cutaneous B-Cell Lymphoma(8/27/2008) Researchers from Germany have reported that Zevalin® (Yttrium-90 [(90)Y] ibritumomab tiuxetan) is effective therapy for patients with primary cutaneous B-cell lymphoma (PCBCL). The details of this study appeared in an early online publication in Leukemia-Lymphoma on July 25, 2008.
Treanda® plus Rituxan® Effective for Recurrent Non-Hodgkin’s Lymphoma(7/17/2008) Researchers from Canada and the United States have reported that the combination of Treanda® (bendamustine) plus Rituxan® (rituximab) provides effective therapy for patients with non-Hodgkin’s lymphoma (NHL) that has stopped responding to prior treatment. These results appeared in an early online publication in the Journal of Clinical Oncology on July 14, 2008.
Gemcitabine, Rituximab, Oxaliplatin, and Pegfilgrastim Active for Relapsed NHL(6/27/2008) Researchers from the M.D. Anderson Cancer Center have reported that the combination of gemcitabine, rituximab, oxaliplatin, and pegfilgrastim compares favorably with other salvage regimens for relapsed non-Hodgkin’s lymphoma (NHL) and is less toxic. The details of this study were presented at the 2008 meeting of the American Society of Clinical Oncology in Chicago May 30-June 2.
NHL Patients Older than 65 Years of Age Benefit from Autologous Stem Cell Transplantation(3/11/2008) Researchers from the MD Anderson Cancer Center have reported a 61% three-year survival following autologous stem cell transplantation in patients over 65 years of age with relapsed non-Hodgkin’s lymphoma (NHL). The details of this study appeared in an early online publication in the Annals of Oncology on February 13, 2008.
Pegylated Liposomal Doxorubicin Effective for Advanced or Refractory Cutaneous T-cell Lymphoma(7/11/2008) Researchers from France have reported an overall response rate of 56% in patients with advanced or refractory cutaneous T-cell lymphoma (CTCL) following treatment with pegylated liposomal doxorubicin (Doxil®, Caelyx®). The details of this study appeared in the June 2008 issue of the Archives of Dermatology.
Allogeneic Stem Cell Transplants May Be Best Option for T-Cell Lymphoma(4/18/2008) Researchers from France affiliated with the Societe Francaise de Greffe de Moelle et de Therapies Cellulaire have reported that allogeneic stem cell transplants are effective therapy for patients with NK/T–cell lymphomas. The details of this study appeared in an early online publication in the Journal of Clinical Oncology on April 7, 2008.
Ninety Minute Infusion of Rituxan® Well Tolerated(4/16/2007) Researchers from Canada have reported that a 90 minute infusion of Rituxan (rituximab) is safe with resultant decrease in time and resource utilization. The details of this study appeared in an early online publication in Blood on January 23, 2007.
Stem Cell Transplantation Effective for T-Cell Lymphomas(2/21/2007) Two studies published in the Annals of Oncology suggest that autologous stem cell transplantation plays a major role in the treatment of patients with T-cell lymphomas.
Interleukin 12 Active in Mycosis Fungoides(11/7/2006) Researchers involved in a multicenter U.S. trial have reported that interleukin-12 (IL-12) produces partial response rate of 43% in patients with previously treated mycosis fungoides.
Ninety Minute Infusion of Rituxan® Well Tolerated(4/16/2007) Researchers from Canada have reported that a 90 minute infusion of Rituxan (rituximab) is safe with resultant decrease in time and resource utilization. The details of this study appeared in an early online publication in Blood on January 23, 2007.
Velcade® Approved for Mantle Cell Lymphoma(12/11/2006) Millennium Pharmaceutical’s agent Velcade (bortezomib) was approved by the United States Food and Drug Administration (FDA) for the treatment of mantle cell lymphoma among patients who have received prior therapy.
Velcade® Confirmed Effective in Patients with Mantle Cell Lymphoma(11/6/2006) A Canadian phase II study has confirmed that Velcade (bortezomib) is an active agent for the treatment of previously untreated and previously treated patients with mantle cell lymphoma (MCL).
Velcade® Effective in Mantle Cell Lymphoma(10/26/2006) A U.S. multicenter trial has determined that Velcade® (bortezomib) is an effective treatment option for patients with relapsed or refractory mantle cell lymphoma (MCL).
Patient Home
